Previous close | 0.2500 |
Open | 0.2500 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.2001 - 0.2500 |
52-week range | 0.1400 - 1.0400 |
Volume | |
Avg. volume | 88,001 |
Market cap | 5.689M |
Beta (5Y monthly) | -0.07 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Pressure BioSciences’ UltraShear Platform for Best-in-Class Nanoemulsions Enables Development and Launch of Health & Wellness Products with Revolutionary Bioavailability, Fast Onset, and EffectivenessSOUTH EASTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” or the “Company”), a leading innovator in high-pressure nanotechnology and a pioneer in the development of novel, broadly-enabling, pressure-based instruments and nanoemulsion products and servic
PBIO Receives Critical Processor License for Industrial Hemp in MA.New License and Relocation to Enhanced Manufacturing Facility Allows Company to Supplement Production with West Coast Partner to Manage Anticipated Onset of Purchase Order Increases. CANTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” or the “Company”), a leading innovator in high-pressure nanotechnology and a pioneer in the development of novel, broadly-enabling, pressure-based inst
Uncle Bud's Reports Early Synergies and Measurable Performance Metrics in First Month Since PBIO Acquisition, Catapulting Company to Increased Heights in Market Presence and Consumer EngagementSOUTH EASTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” or the “Company”), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industri